Join our ImmunoCommunity and share your story!
"There's no question in my mind that immunotherapy saved my life."
For Mary Elizabeth Williams, a New York-based writer and mother of two, the hardest part of having stage 4 melanoma was imagining what her family would do without her. Her spouse, and her daughters, then age 7 and 11—how would they cope with the loss?
In late 2011, that thought loomed in Mary Elizabeth’s mind as she prepared to begin conventional treatment for what all medical sources told her was a terminal illness. Then, at the last minute, she learned she was eligible for clinical trial of a promising new immunotherapy being conducted by Jedd Wolchok, M.D., Ph.D., at Memorial Sloan Kettering Cancer Center in New York City. The trial was a study of two checkpoint inhibitor drugs, ipilimumab and nivolumab (made by Bristol Myers-Squibb), for patients with metastatic melanoma. Both drugs are antibodies directed at specific “braking” molecules, called checkpoints, on immune cells. By “taking the brakes off” the immune response, the drugs enable a more powerful anti-cancer response.
Mary Elizabeth began treatment with the two immunotherapy drugs in November 2011. By January 2012, she knew the treatment was working. The Answer to Cancer (TheA2C) spoke with Mary Elizabeth about her cancer treatment journey.
Others may benefit from hearing your experience and treatment journey.
When doctors told Sergei German, 54, that his cancer warranted a watch-and-wait approach, he was unsettled. He knew...
Everyone needs an advocate sometimes. For KayEllen Gebhart, 61, who was facing stage 3 ovarian cancer, that...
As an army spouse, Diane Altenburg, 67, is used to serving others. She sits on the board of the National Military...
Join the ImmunoCommunity to access an important resource for all things related to cancer immunotherapy. Connect with others who have shared experiences and learn about new treatment options.
To continue to find the answers to cancer, it takes funding for research. Donate to the Cancer Research Institute today to help us continue to search for answers.